EIKN (Eikon Therapeutics) EBIT: $-167.04 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EIKN Eikon Therapeutics Inc EIKN
12 GF Score
Price $9.84
View Full Analysis

What is Eikon Therapeutics EBIT?

Eikon Therapeutics EIKN -3.40% 12 EBIT is $-167.04 Mil as of Mar. 2026. GuruFocus rates EIKN with a GF Score™ of 12/100.

Eikon Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-87.34 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-167.04 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eikon Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -116.81%. Eikon Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -150.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Eikon Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -60.66%.

Eikon Therapeutics  (NAS:EIKN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eikon Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-349.348 * ( 1 - 0% )/( (255.88 + 342.272)/ 2 )
=-349.348/299.076
=-116.81 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=594.734 - 44.944 - ( 335.975 - max(0, 55.007 - 348.917+335.975))
=255.88

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=850.826 - 24.117 - ( 512.182 - max(0, 45.064 - 529.501+512.182))
=342.272

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Eikon Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-349.348/( ( (233.863 + max(-32.037, 0)) + (229.133 + max(-18.005, 0)) )/ 2 )
=-349.348/( ( 233.863 + 229.133 )/ 2 )
=-349.348/231.498
=-150.91 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 12.942) - (44.944 + 0 + 0.034999999999997)
=-32.037

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 17.319) - (24.117 + 0 + 11.207)
=-18.005

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eikon Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-167.04/275.370
=-60.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eikon Therapeutics EBIT Related Terms

Eikon Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Eikon Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eikon Therapeutics EBIT Chart

Eikon Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
EBIT
-241.96 -243.78 -323.41

Eikon Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial -64.92 -71.38 0.00 -79.70 -87.34

EIKN vs PRME, CRMD, STTK: EBIT Comparison

For the Biotechnology subindustry, Eikon Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eikon Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eikon Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eikon Therapeutics's EV-to-EBIT falls into.


EIKN
12GF Score
Eikon Therapeutics Inc EIKN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eikon Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-167.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-167.04 Mil mean?
Eikon Therapeutics (EIKN) has a EBIT of $-167.04 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eikon Therapeutics.
Is Eikon Therapeutics' EBIT too high?
Eikon Therapeutics' current EBIT is $-167.04 Mil. Overall, Eikon Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Eikon Therapeutics' EBIT compare to PRME and CRMD?
Eikon Therapeutics' EBIT of $-167.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eikon Therapeutics. Eikon Therapeutics's current EBIT is $-167.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eikon Therapeutics stock overvalued right now?
Eikon Therapeutics (EIKN) has a current EBIT of $-167.04 Mil. The current EBIT is $-167.04 Mil. Eikon Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Eikon Therapeutics (EIKN), the current EBIT is $-167.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eikon Therapeutics Business Description

Address 230 Harriet Tubman Way, Millbrae, CA, USA, 94030
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
12GF Score

Get the complete analysis for EIKN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.84
Price